Health Care [ 4/12 ] | Pharmaceuticals [ 14/72 ]
NASDAQ | Common Stock
Cara Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of pruritus in the United States.
The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.
Its product candidate, including Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica.
Cara Therapeutics, Inc. has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. and Winhealth Pharma for the co-development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis in China; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea.
The company was incorporated in 2004 and is based in Stamford, Connecticut.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 13, 24 | -0.56 Decreased by -14.29% | -0.40 Decreased by -40.00% |
| Mar 27, 24 | -0.59 Decreased by -5.36% | -0.41 Decreased by -43.90% |
| Nov 13, 23 | -0.52 Decreased by -20.93% | -0.52 |
| Aug 7, 23 | -0.58 Decreased by -625.00% | -0.54 Decreased by -7.41% |
| May 15, 23 | -0.49 Increased by +5.77% | -0.52 Increased by +5.77% |
| Mar 6, 23 | -0.56 Increased by +11.11% | -0.32 Decreased by -75.00% |
| Nov 7, 22 | -0.43 Decreased by -2.05 K% | -0.42 Decreased by -2.38% |
| Aug 8, 22 | -0.08 Increased by +86.89% | -0.25 Increased by +68.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 4.87 M Decreased by -55.00% | -28.03 M Decreased by -24.50% | Decreased by -576.08% Decreased by -176.67% |
| Jun 30, 23 | 6.93 M Decreased by -69.86% | -31.48 M Decreased by -698.96% | Decreased by -454.05% Decreased by -2.55 K% |
| Mar 31, 23 | 6.17 M Increased by +28.71% | -25.68 M Increased by +6.91% | Decreased by -416.55% Increased by +27.67% |
| Dec 31, 22 | 3.26 M Increased by +297.20% | -29.37 M Increased by +12.02% | Decreased by -900.67% Increased by +77.85% |
| Sep 30, 22 | 10.81 M Decreased by -46.66% | -22.52 M Decreased by -2.12 K% | Decreased by -208.22% Decreased by -4.07 K% |
| Jun 30, 22 | 23.00 M Increased by +N/A% | -3.94 M Increased by +87.18% | Decreased by -17.13% Decreased by N/A% |
| Mar 31, 22 | 4.79 M Increased by +147.55% | -27.59 M Decreased by -18.39% | Decreased by -575.93% Increased by +52.17% |
| Dec 31, 21 | 821.00 K Decreased by -99.27% | -33.38 M Decreased by -142.30% | Decreased by -4.07 K% Decreased by -5.88 K% |